aid: amply-discovery
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/amply-discovery.png
name: AMPLY Discovery
description: >-
  AMPLY Discovery is a UK (Belfast, Northern Ireland) biotechnology company
  turning the roughly 98% of the genome largely ignored by drug developers —
  the "dark genome" — into a pipeline of first-in-class therapeutics. The
  company pairs six AI/computational discovery engines with two wet labs in a
  closed loop between silicon and bench to find novel antimicrobial and
  therapeutic candidates targeting drug-resistant pathogens and complex
  diseases. AMPLY is a Techstars portfolio company and has been backed by
  Innovate UK, Invest NI, QUBIS and other UK/NI innovation programmes. It is
  tracked in the API Evangelist network as a company profile; AMPLY Discovery
  publishes no public developer API, documentation, SDKs, or machine-readable
  API surface at this time.
url: https://raw.githubusercontent.com/api-evangelist/amply-discovery/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- techstars
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biotechnology
- Drug Discovery
- Artificial Intelligence
- Genomics
- Pharmaceuticals
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://amplydiscovery.com/
- type: Blog
  url: https://amplydiscovery.com/category/news/
- type: LinkedIn
  url: https://www.linkedin.com/company/amply-discovery
- type: Email
  url: mailto:contact@amplydiscovery.com
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence